Heartflow (NASDAQ:HTFL) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says

Heartflow (NASDAQ:HTFL) had its price target lifted by stock analysts at Stifel Nicolaus from $45.00 to $70.00 in a report issued on Friday, Benzinga reports. The firm presently has a “buy” rating on the stock. Stifel Nicolaus‘s target price would suggest a potential upside of 16.82% from the company’s previous close.

Several other equities research analysts have also recently commented on HTFL. Weiss Ratings reiterated a “sell (d-)” rating on shares of Heartflow in a research report on Wednesday, November 4th. JPMorgan Chase & Co. increased their price objective on shares of Heartflow from $35.00 to $45.00 and gave the company an “overweight” rating in a report on Friday, August 14th. Wells Fargo & Company increased their price objective on shares of Heartflow from $37.00 to $39.00 and gave the company an “overweight” rating in a report on Friday, August 14th. Robert W. Baird raised their price objective on shares of Heartflow from $56.00 to $68.00 and gave the company an “outperform” rating in a research note on Friday. Finally, Morgan Stanley lifted their target price on shares of Heartflow from $35.00 to $40.00 and gave the stock an “equal weight” rating in a report on Friday, August 14th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Heartflow has an average rating of “Moderate Buy” and an average target price of $54.62.

Heartflow Stock Up 1.4%

Shares of HTFL stock opened at $59.92 on Friday. The stock has a 50-day moving average price of $51.93 and a 200 day moving average price of $35.14. The firm has a market cap of $5.21 billion, a price-to-earnings ratio of -32.74 and a beta of 2.50. Heartflow has a 12 month low of $20.13 and a 12 month high of $60.65.

Heartflow (NASDAQ:HTFL) last announced its quarterly earnings data on Thursday, November 12th. The company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.15. Heartflow had a negative return on equity of 23.52% and a negative net margin of 55.82%. The firm had revenue of $72.86 million during the quarter. During the same period in the prior year, the firm posted ($0.27) earnings per share. Sell-side analysts predict that Heartflow will post -0.75 earnings per share for the current fiscal year.

Insider Transactions at Heartflow

In related news, CEO John Farquhar sold 38,900 shares of the firm’s stock in a transaction on Monday, October 12th. The stock was sold at an average price of $49.57, for a total transaction of $1,928,273.00. Following the sale, the chief executive officer owned 283,014 shares of the company’s stock, valued at approximately $14,029,003.98. This trade represents a 12.08% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Campbell Rogers sold 23,933 shares of the firm’s stock in a transaction dated Thursday, October 22nd. The stock was sold at an average price of $55.01, for a total value of $1,316,554.33. Following the sale, the insider directly owned 73,453 shares in the company, valued at approximately $4,040,649.53. This represents a 24.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 332,403 shares of company stock valued at $16,602,786 over the last three months. 7.70% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. First Trust Advisors LP bought a new stake in shares of Heartflow during the third quarter worth $1,931,000. Teachers Retirement System of The State of Kentucky bought a new stake in Heartflow in the 3rd quarter valued at $1,684,000. Allworth Financial LP lifted its position in Heartflow by 116.4% in the 3rd quarter. Allworth Financial LP now owns 1,145 shares of the company’s stock valued at $57,000 after acquiring an additional 616 shares in the last quarter. Pier 88 Investment Partners LLC acquired a new position in Heartflow in the 3rd quarter worth $174,000. Finally, M&G PLC bought a new position in Heartflow during the 3rd quarter worth about $15,978,000.

Latest Heartflow News

These are some of the HTFL news items that stood out recently:

• Positive Sentiment: Third-quarter revenue rose 57% year over year to $72.9 million, exceeding the roughly $65.2 million analyst estimate. The loss was $0.03 per share, narrower than both the expected $0.18 loss and the $0.27 loss a year earlier. HeartFlow Reports Q3 Loss, Beats Revenue Estimates
• Positive Sentiment: Heartflow raised its 2026 revenue guidance to $262 million–$264 million, above the approximately $248.6 million consensus estimate. The higher outlook may signal stronger growth expectations. Heartflow Expects 2026 Revenue of $262M–$264M
• Negative Sentiment: CEO insider selling may weigh on sentiment: the CEO sold $2.17 million of Heartflow stock. A sale by itself does not establish the reason for the transaction. Heartflow CEO Sells $2.17 Million in Stock

About Heartflow

HeartFlow, Inc. is a medical technology company that develops noninvasive tools to help clinicians assess coronary artery disease. Its platform analyzes coronary CT angiography scans to create personalized models of a patient’s coronary arteries and provide information that can support diagnosis and treatment planning. The company’s offerings include HeartFlow FFR CT Analysis, which estimates blood flow and the effects of artery narrowing, and tools for assessing coronary plaque. The technology combines medical imaging with computational analysis and artificial intelligence, giving clinicians information without requiring an invasive procedure to measure blood flow.